To anyone who has tried losing weight, this scenario is familiar: a man cuts carbs and drops 10 pounds, while a woman on the same plan loses just 2. For years, research has shown men typically respond faster to diet and exercise than women—making recent clinical trial results surprising: injectable GLP-1 weight-loss drugs appear more effective for women on average.
A landmark study, presented at the European Congress on Obesity and published in The New England Journal of Medicine, compared two GLP-1 drugs: semaglutide (Wegovy) and tirzepatide (Zepbound). Around 750 obese patients received maximum tolerated doses, with Zepbound outperforming Wegovy by 50% in weight loss. Notably, trial participants lost slightly less weight than in prior studies—attributed largely to male subjects, who shed 6% less than women. The trial’s 35% male composition (higher than the 20–25% in earlier research) may have contributed.
Dr. Louis Aronne, lead author and weight control expert, confirmed this recurring pattern: “Women’s better response is real and encouraging, though the exact cause remains unclear.” Previous long-term trials supported this: women lost 11% of body weight on semaglutide (vs. 8% for men) and up to 28% on tirzepatide (vs. 19% for men).
Experts cite multifaceted reasons. Dosage plays a role: women, typically lighter than men, receive the same doses, leading to relatively stronger effects. Fat distribution matters too—women have more subcutaneous fat (under skin), while men have more visceral fat (around organs), and the drugs may target certain fat types better. Behavioral factors include greater weight-loss pressure on women, boosting adherence, and higher tolerance for side effects like nausea compared to men, who often discontinue treatment earlier.
Estrogen research offers compelling insights. Dr. Karolina Skibicka’s animal studies show estrogen amplifies GLP-1’s appetite-suppressing effects by increasing cellular receptors. Blocking estrogen reduces drug effectiveness, though these findings are still early.
Gender-specific effects extend beyond weight loss: women report more gastrointestinal side effects but greater fat reduction, while men may gain more cardiovascular benefits. Some evidence links GLP-1 use to mood changes in women, including depression.
Understanding these differences is critical for personalized care—especially for postmenopausal women or breast cancer survivors with reduced estrogen. As Dr. Melanie Jay notes: “Men and women differ physiologically—we can’t rely on one-size-fits-all treatments. Men may need adjusted dosing or supplements to match women’s results.”
发表回复